T h e ne w e ngl a nd jou r na l o f m e dic i ne n engl j med 359;26 www.nejm.org december 25, 2008 2846 peripheral-blood smear showed macroovalocytes (Fig. 1A, arrowheads) and hyper segmented neutrophils (Fig. 1A, arrow) . A bone marrow aspirate, performed to evaluate pancyto penia, showed megaloblastic erythroid precursors (Fig. 1B , arrowheads) and giant bands (Fig. 1B, arrow) . The patient was treated with folic acid, 5 mg daily by mouth for 2 months, and vitamin B 12 replacement. A complete blood count obtained 7 months later showed a normalization of the red-cell count indexes. Pernicious anemia is suspected but has not been confirmed. Editor's note: We received 1520 responses for this medical mystery, from 86 countries. Sixtyfive percent of respondents were practicing physicians, 20% were physicians in training, 11% were medical students, and the remaining 4% were other readers. Overall, 77% of respondents identified some type of megaloblastic anemia, and two thirds of this group specifically suggested a diagnosis of vitamin B 12 deficiency or pernicious anemia. The remaining 23% of respondents suggested other diagnoses: 17% suggested an alternative hematologic process, such as an acute or chronic leukemia, multiple myeloma, Waldenström's macroglobulinemia, or polycythemia vera, and 6% suggested other conditions, including babesiosis, malaria, parvovirus B19, leishmaniasis, or poisoning with lead or arsenic.
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More on Propranolol for Hemangiomas of Infancy
To the Editor: The response of infantile hemangiomas to propranolol reported in the letter by Léauté-Labrèze et al. (June 12 issue) 1 catapulted the use of this treatment to first-line status among physicians managing this disease. Not included in their letter was a discussion about initiating and monitoring propranolol use, or about potential risks, which may be unique among these patients. The most common serious adverse effects are bradycardia and hypotension. Infants with very large hemangiomas or miliary hemangiomatosis are at risk for high-output cardiac compromise. 2 Propranolol may mask the clinical signs of early cardiac failure and diminish cardiac performance. Propranolol may also blunt the clinical features of hypoglycemia. Sustained hypoglycemia in infancy has been associated with longterm neurologic sequelae. 3 We know of two infants who had unrecognized side effects from propranolol.
We developed a treatment protocol to optimize safety: baseline echocardiography and 48-hour hospitalization or home nursing visits to monitor vital signs and blood glucose levels. Medication is given every 8 hours, with an initial dose of 0.16 mg per kilogram of body weight. If the vital signs and glucose levels remain normal, the dose is incrementally doubled to a maximum of 0.67 mg per kilogram (to a maximum daily dose of 2.0 mg per kilogram). Propranolol should be gradually tapered over a period of 2 weeks. Gottschling S, Schneider G, Meyer S, Reinhard H, Dill-correspondence case of death or serious cardiovascular disease as a direct result of exposure to a beta-blocker. 1 Side effects of beta-blockers are well known; these include transient bradycardia and hypotension that warrant close monitoring at the onset of treatment. Bronchospasm is usually seen as an exacerbation in patients with underlying reactive airways; a family history with regard to atopy or repeated wheezing should be obtained. Betablockers decrease lipolysis, glycogenolysis, and gluconeogenesis that predispose patients to hypoglycemia. They also mask some beta-sympathetic-related hypoglycemic symptoms. The first week of life is a critical period when neonates gradually reach their optimal milk intake and spontaneous hypoglycemia is more likely to develop; beta-blockers clearly should be avoided during this period. Most infants treated for an infantile hemangioma are older and have a normal food intake, and the conditions described in the article by Burns et al. 2 do not apply. A large multicenter study is in the planning stage. We hope that this study will lead to elaborate, reasonable, and objective recommendations concerning the use of beta-blockers in this indication.
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